SCHEMBL17767390

SCHEMBL17767390

CCC(=O)O[C@@H]1O[C@H](CO)[C@@H](O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LGALS8 O00214 4/20 0.51
LGALS3 P17931 3/20 0.51
LGALS4 P56470 2/20 0.51
LGALS9 O00182 1/20 0.47
LGALS1 P09382 1/20 0.47
LGALS7; LGALS7B P47929 1/20 0.47
IGF2R P11717 1/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
AMY1A P0DUB6 1/20 0.45
GAA P10253 1/20 0.44
PYGB P11216 1/20 0.44
CA12 O43570 2/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA9 Q16790 2/20 0.43
CA14 Q9ULX7 2/20 0.43
FGF1 P05230 1/20 0.43
FGF2 P09038 1/20 0.43
VEGFA P15692 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7215928 0.90 PYGB (0.53) LGALS8GAAPYGB
SCHEMBL9507333 0.90 PYGB (0.53) LGALS8GAAPYGB
SCHEMBL7702025 0.86 LGALS8 (0.52) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL11131327 0.86 LGALS8 (0.46) LGALS8LGALS3LGALS4AMY1AGAA
SCHEMBL5086308 0.86 LGALS3 (0.53) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL5544380 0.86 LGALS3 (0.53) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL17767368 0.85 LGALS8 (0.48) LGALS8LGALS3LGALS4LGALS9LGALS1
SCHEMBL11504400 0.85 GJB2 (0.52) LGALS8LGALS3LGALS4
SCHEMBL9347500 0.85 GJB2 (0.52) LGALS8LGALS3LGALS4
SCHEMBL22034095 0.85 GJB2 (0.52) LGALS8LGALS3LGALS4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115501172-A Gel formulations for topical drug delivery 丹麦技术大学 2022-12-23 CN disclosed
CN-107249570-B Gel formulations for topical drug delivery 丹麦技术大学 2022-08-09 CN disclosed
US-20210386669-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2021-12-16 US disclosed
US-11065201-B2 Gel formulations for local drug release TECHNICAL UNIVERSITY OF DENMARK (DK) 2021-07-20 US disclosed
US-20180325819-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2018-11-15 US disclosed
EP-3220887-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE Technical University of Denmark (DK) 2017-09-27 EP disclosed
WO-2016079332-A1 GEL FORMULATIONS FOR IMPROVING IMMUNOTHERAPY TECHNICAL UNIVERSITY OF DENMARK (DK) 2016-05-26 WO disclosed
WO-2016079331-A1 GEL FORMULATIONS FOR ENHANCING THE EFFECT OF RADIOTHERAPY TECHNICAL UNIVERSITY OF DENMARK (DK) 2016-05-26 WO disclosed
WO-2016079330-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TECHNICAL UNIVERSITY OF DENMARK (DK) 2016-05-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11065201-B2 Gel formulations for local drug release TREH, GALE, SLC2A8 LGALS8 19/4885LGALS3 40/4885LGALS4 58/4885
US-20180325819-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TREH, GALE, SLC2A8 LGALS8 19/4885LGALS3 40/4885LGALS4 58/4885
US-20210386669-A1 GEL FORMULATIONS FOR LOCAL DRUG RELEASE TREH, GALE, SLC2A8 LGALS8 19/4885LGALS3 40/4885LGALS4 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.